Where Do Telehealth Companies Get Their Semaglutide?

Channel one: branded product through pharmacy channels

The FDA-approved GLP-1s reach patients the way any branded prescription does: a clinician prescribes, and a licensed dispensing pharmacy (retail, mail-order, or a program's fulfillment partner) fills from wholesale distribution. The manufacturers have also built direct cash-pay channels with published pricing tiers, which changed the market's economics: a program offering branded product now competes with, and sometimes routes through, the manufacturers' own pipes.

For a program, branded supply is the legally simplest channel and the economically hardest: acquisition costs are high, availability has stabilized since the shortage era, and your program's value has to live in the care experience and convenience rather than a price gap. Programs serious about branded supply verify one thing above all: that their dispensing pharmacy holds non-resident licenses for every state they ship into.

Channel two: 503A compounding, on patient-specific grounds

During the official shortages, compounding pharmacies could lawfully produce versions of the branded GLP-1s at scale, and an industry grew on that basis. With the shortages resolved in 2025, that era ended: compounding what is essentially a copy of a commercially available drug is generally impermissible, and the 503A channel that remains rests on patient-specific clinical difference (a prescriber's documented judgment that a particular formulation, dose, or form serves a particular patient), a basis whose outer limits FDA and the manufacturers are actively contesting, warning letters included.

What that means practically for a program: compounded supply is not a commodity you shop on price. The diligence questions are legal before they are commercial: on what specific basis does this pharmacy compound this product today; how is patient-specific justification documented on each prescription; which states is it licensed to ship into; and what is its regulatory history. A pharmacy that answers crisply in writing is a potential partner; one that waves at 'the personalization exception' without documentation is your future co-defendant.

The one question that sorts compounded suppliers instantly: 'Show me, in writing, the legal basis on which you compound this product today.' Crisp answer, real partner. Hand-waving, walk away.

Channel three: the 503B channel, mostly history for GLP-1s

503B outsourcing facilities (the larger-batch, federally overseen compounding tier) supplied programs at scale during the shortages. Post-resolution, their lane depends on FDA's bulk-substances framework, where the GLP-1 entries have been the contested question; large-batch GLP-1 production is not the live channel it was, and programs still describing '503B supply' deserve the same in-writing legal-basis question as everyone else, with extra skepticism about whether the answer is current.

The 503A-versus-503B distinction still matters everywhere else in your formulary (it governs office stock, batch sizes, and oversight for many non-GLP-1 products), which is why our dedicated guide covers it in full.

Channel four: the routes that are not a channel

Research-chemical websites selling 'not for human consumption' vials, gray importation, and wholesale-and-resell schemes are how programs end, not how they supply. The 'research use only' label is not a loophole; it is a documented red flag that certification reviewers and regulators treat as evidence of exactly what it looks like. Any plan that involves your business taking possession of drug product without pharmacy licensure has already failed the structure test, whatever the label says.

The tell that a founder is drifting this way is always economics: gray supply is cheap because it carries none of the costs of being legal. The programs that last treat supply cost as the price of existing, and build margin in retention and program value instead.

How programs actually wire supply (and what to get in writing)

Operationally, supply is a routing question: prescriptions flow from the clinical layer to one or more pharmacies via e-prescribing integrations, with routing logic for state licensure, product availability, and cost. Assembled stacks negotiate this pharmacy by pharmacy; operated platforms carry an integrated supply network and put medication economics inside the rate (EmbedCare's GLP-1 programs include medication in flat product rates, on supply the platform routes and verifies).

Whatever path you take, the writing-things-down list is the same: the legal basis for each compounded product, the state-licensure map against your patient map, the per-fill economics (or the medication-included rate), shipping and cold-chain commitments, and what happens when a product's regulatory status moves. That last one is not hypothetical in this category; it is the recent history of it.